For a patient with distal esophageal adenocarcinoma with residual disease after FOLFOX x3 cycles + RT followed by surgery, would you recommend adjuvant chemotherapy or adjuvant nivolumab?

CM577 has simultaneously done 2 things: established nivolumab as a standard-of-care in this setting but also hopefully discourages/eliminates the use of adjuvant chemotherapy. There are absolutely no data to justify giving more or different chemotherapy to such patients. Remember, the control arm of...

I'm going to assume that you're referring to residual pathologic disease. In this scenario (neoadjuvant chemoradiation followed by surgery), there is no evidence that adjuvant chemotherapy can reduce the risk of recurrence. I would recommend adjuvant nivolumab based on the reported CM577 data. This ...

I would consider adj Nivolumab, but only in CPS >5%, since subgroup analysis (appendix of the NEJM publication) showed little to no benefit outside this subgroup.